IL-UNITAS-GLOBAL
22.2.2021 14:03:13 CET | Business Wire | Press release
Unitas Global announces the availability of Unitas Reach™ , the first global software defined network (SDN) to offer automated ubiquitous edge access to any cloud location. Enterprises are finding that current networks are a bottleneck to the adoption of new technologies and capabilities – these problems have not been resolved, until now. Unitas Reach™ is the industry's first purpose-built network connecting cloud providers, carrier-neutral data centers, SaaS applications, and edge access networks to form a multi-service global interconnection fabric.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005156/en/
"Organizations today need flexible, proven, and secure infrastructure to run their enterprise applications and multi-cloud solutions," shares Patrick Shutt, CEO of Unitas Global. "With Unitas Reach™, our clients achieve cost-optimized network connectivity with the agility needed to scale quickly and support the growing demands of applications on network architectures, performance, and costs."
Unitas Reach™ is built to provide connectivity options that different modern cloud services require with simple integration to traditional enterprise networks. With its presence on six continents, Unitas Reach™ provides redundant and diverse Internet, IP, Ethernet, and Wave access to distributed applications across any cloud, hybrid-cloud, multi-cloud, or private cloud destination. Strategic interconnections with hundreds of other networks and fiber access providers further extends the network access to the edge, including over 900 carrier neutral data centers and 30 million enterprise locations in over 85 countries. Sophisticated automation, monitoring, and orchestration to the edge make the entire interconnect fabric unmatched in enabling complete flexibility in service creation and scaling capacity as enterprise networking needs change.
"We designed Unitas Reach™ in response to the dynamic networking requirements that today's businesses require and have yet to experience," comments Grant Kirkwood, Founder and CTO of Unitas Global. "Providers and enterprises can easily add connectivity to dynamically support their ever changing network strategies, and customize capabilities to their unique set of service delivery, operations, access and configuration requirements.”
Unitas' edge to everywhere connectivity solutions offer providers and enterprises with automated:
- Cloud On-ramps™ for multi-cloud delivery
- High performance managed Internet
- Direct connectivity to and between multi-cloud platforms
- Agile and scalable WAN solutions
Unitas Reach™ provides the greatest choice and ease of use for provisioning enterprises with connectivity that delivers agile, cost-effective, low-latency connections to optimize application performance. Unitas Global solves the enterprise challenge by going to market with MSPs, hyperscalers, and data centers who are able to establish an on-net point of presence with Unitas Reach™ to expand their network coverage, scale services everywhere, and locate applications as close to customers as possible to improve performance and optimize costs.
Learn more about Unitas Reach™ and its edge to everywhere connectivity solution.
About Unitas Global
Unitas Global is a global managed network service provider offering automated ubiquitous edge access to any cloud, everywhere. The company provides the most agile connected multi-cloud environments that are easy-to-consume, fully managed, and backed by a promise to deliver the best application performance. Connect with Unitas at LinkedIn , Twitter , and its Blog .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005156/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom